These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25585966)

  • 1. Novel investigational drugs targeting IL-6 signaling for the treatment of depression.
    Fonseka TM; McIntyre RS; Soczynska JK; Kennedy SH
    Expert Opin Investig Drugs; 2015 Apr; 24(4):459-75. PubMed ID: 25585966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?
    Maes M; Anderson G; Kubera M; Berk M
    Expert Opin Ther Targets; 2014 May; 18(5):495-512. PubMed ID: 24548241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hitting a complex target: an update on interleukin-6 trans-signalling.
    Waetzig GH; Rose-John S
    Expert Opin Ther Targets; 2012 Feb; 16(2):225-36. PubMed ID: 22324903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Interleukin-6 From molecular mechanisms of signal transduction to physiological properties and therapeutic targeting].
    Drutskaya MS; Nosenko MA; Atretkhany KS; Efimov GA; Nedospasov SA
    Mol Biol (Mosk); 2015; 49(6):937-43. PubMed ID: 26710772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target.
    Goeldner C; Ballard TM; Knoflach F; Wichmann J; Gatti S; Umbricht D
    Neuropharmacology; 2013 Jan; 64():337-46. PubMed ID: 22992331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nitric oxide: Antidepressant mechanisms and inflammation.
    Ghasemi M
    Adv Pharmacol; 2019; 86():121-152. PubMed ID: 31378250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers.
    Ho LJ; Luo SF; Lai JH
    Biochem Pharmacol; 2015 Sep; 97(1):16-26. PubMed ID: 26080005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treat the brain and treat the periphery: toward a holistic approach to major depressive disorder.
    Zheng X; Zhang X; Wang G; Hao H
    Drug Discov Today; 2015 May; 20(5):562-8. PubMed ID: 25849660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene of the month: Interleukin 6 (IL-6).
    Ataie-Kachoie P; Pourgholami MH; Richardson DR; Morris DL
    J Clin Pathol; 2014 Nov; 67(11):932-7. PubMed ID: 25031389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antidepressant effect of whole-body hyperthermia is associated with the classical interleukin-6 signaling pathway.
    Mac Giollabhui N; Lowry CA; Nyer M; Foster SL; Liu RT; Smith DG; Cole SP; Mason AE; Mischoulon D; Raison CL
    Brain Behav Immun; 2024 Jul; 119():801-806. PubMed ID: 38677624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
    Rose-John S; Scheller J; Elson G; Jones SA
    J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-6/IL-6 receptor system and its role in physiological and pathological conditions.
    Mihara M; Hashizume M; Yoshida H; Suzuki M; Shiina M
    Clin Sci (Lond); 2012 Feb; 122(4):143-59. PubMed ID: 22029668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6 and its receptors: a highly regulated and dynamic system.
    Wolf J; Rose-John S; Garbers C
    Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
    Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
    Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs.
    Semerano L; Thiolat A; Minichiello E; Clavel G; Bessis N; Boissier MC
    Expert Opin Investig Drugs; 2014 Jul; 23(7):979-99. PubMed ID: 24766460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease.
    Mitsuyama K; Matsumoto S; Masuda J; Yamasakii H; Kuwaki K; Takedatsu H; Sata M
    Anticancer Res; 2007; 27(6A):3749-56. PubMed ID: 17970038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-6 trans-signalling in chronic inflammation and cancer.
    Scheller J; Ohnesorge N; Rose-John S
    Scand J Immunol; 2006 May; 63(5):321-9. PubMed ID: 16640655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery.
    Dahl J; Ormstad H; Aass HC; Malt UF; Bendz LT; Sandvik L; Brundin L; Andreassen OA
    Psychoneuroendocrinology; 2014 Jul; 45():77-86. PubMed ID: 24845179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis.
    Mees ST; Toellner S; Marx K; Faendrich F; Kallen KJ; Schroeder J; Haier J; Kahlke V
    J Surg Res; 2009 Dec; 157(2):235-42. PubMed ID: 19589542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis.
    Liu JJ; Wei YB; Strawbridge R; Bao Y; Chang S; Shi L; Que J; Gadad BS; Trivedi MH; Kelsoe JR; Lu L
    Mol Psychiatry; 2020 Feb; 25(2):339-350. PubMed ID: 31427752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.